Baidu
map

医改大潮中的医药代表 转型后仍有可为

2017-02-15 王琦琛 健康界

医药代表的职业定位,我国早已有之。如今举国医改,力推两票制、零差价,严管药品流通,医药代表职能转型势在必行。



医药代表的职能日前得到官方定位:不得承担销售任务,只能从事学术推广、技术咨询等活动。

在长久以来“以药养医”背景之下,医药代表提成、回扣问题饱受百姓诟病。如今,零差价和两票制已然成为医改关键词,医药代表注定在这场医改浪潮中华丽转身。

国务院发文定调医药代表职能

2月9日,国务院办公厅发布《国务院办公厅关于进一步改革完善药品生产流通使用政策的若干意见》(下称《意见》),明确提出“食品药品监管部门要加强对医药代表的管理,建立医药代表登记备案制度,备案信息及时公开。医药代表只能从事学术推广、技术咨询等活动,不得承担药品销售任务,其失信行为记入个人信用记录。”

出台《意见》是我国规范、管理医药代表的一系列努力中的最新举措,为规范药品市场,破除“以药养医”提供了新的政策依据。

医药代表早有职业定位

事实上,医院代表在我国早有职业定位。

上世纪八十年代,医药代表制度进入中国。2006年,中国化学制药工业协会起草《医药代表行为准则(讨论稿)》,将医药代表的主要职责定位为倡导科学推广,辅助合理用药。2015年版《中华人民共和国职业分类大典》录入医药代表这一职业,将其定义为“代表药品生产企业,从事药品信息传递、沟通、反馈的专业人员”。

从以上定位看来,医药代表不具备销售职能,难有利益输送。不过,众所周知,医药代表的工作在中国早已“变味儿”,医药代表直接参与药品销售。

“以药养医”导致利益输送

医药代表与医生之间的利益输送多受诟病,并被曝光。

2016年12月,央视播出《高回扣下的高药价》,曝光部分医药代表与大医院医生“统方”、吃回扣的怪现状。央视称,部分药品的药价当中10%是医药代表的提成,另外20%到50%是医生开药所得的回扣。

詹积富:让300万药代消失

面对屡禁不止的怪现状,中国医师协会副秘书长谢启麟表示,我国早已明确医药代表的职业定义,只是部分企业依然我行我素。

对于医药代表,三明医改总舵手詹积富曾做出强硬表态:如果全国300万医药代表大军不消失,不转行,老百姓不可能不吃冤枉药,开冤枉刀,花冤枉钱!

詹积富的言论引来业内一片喧嚣。而针对医药代表职能的争论也随之被推向高峰。

定位明确:医药代表仍有可为

值得注意的是,医药代表不直接参与药品销售并不意味着群体失业,而是职能的整体转型。国家明确其职业定位之后,医药代表仍大有可为。

谢启麟表示,国务院如今建立登记备案制度,有助于摸清医药代表的真实情况。在他看来,医药代表可以为医生提供药品咨询服务和药品最新信息。所以,医药代表有能力对医疗事业的发展做出贡献。

2016年6月,中国中药协会秘书长王桂华也曾表示,中国医药代表要走向职业化和正规化,在培训、管理和评估等方面还有工作要做。如果医药代表的专业知识和职业素养得到保证,相信他们在促进医药双方的健康发展方面大有可为。

本文参考:中国政府网、国家卫计委网站、国家中医药管理局网站、湖南省卫计委网站、央视新闻、中国新闻网、每日经济新闻、新京报、39健康网、凤凰健康等。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666644, encodeId=feaa1666644c0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Feb 16 01:24:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286633, encodeId=4614128663303, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408828, encodeId=ae03140882872, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443577, encodeId=c33514435e78b, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176279, encodeId=90691e627902, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Feb 15 15:49:42 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-16 fengyqf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666644, encodeId=feaa1666644c0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Feb 16 01:24:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286633, encodeId=4614128663303, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408828, encodeId=ae03140882872, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443577, encodeId=c33514435e78b, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176279, encodeId=90691e627902, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Feb 15 15:49:42 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-17 tidiq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1666644, encodeId=feaa1666644c0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Feb 16 01:24:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286633, encodeId=4614128663303, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408828, encodeId=ae03140882872, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443577, encodeId=c33514435e78b, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176279, encodeId=90691e627902, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Feb 15 15:49:42 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-17 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666644, encodeId=feaa1666644c0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Feb 16 01:24:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286633, encodeId=4614128663303, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408828, encodeId=ae03140882872, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443577, encodeId=c33514435e78b, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176279, encodeId=90691e627902, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Feb 15 15:49:42 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1666644, encodeId=feaa1666644c0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Feb 16 01:24:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286633, encodeId=4614128663303, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408828, encodeId=ae03140882872, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443577, encodeId=c33514435e78b, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 17 05:24:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176279, encodeId=90691e627902, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Feb 15 15:49:42 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-15 李东泽

    很好,不错,以后会多学习

    0

相关资讯

八年医改 喜忧参半

新年钟声敲响,新医改正式迈入第八个年头。八年抗日战争已经取得胜利,但医改进行了8个年头仍然还在路上,正在进行万里长征的爬雪山过草地,医改的难度可见一斑。8年不算长,但也不算短,在此辞旧迎新之际,我们要检讨一下过去的得失,以校正未来的计划。过去8年 有喜有忧过去8年的医改将目光聚焦百姓体验感,可以说是一种善的指向。善就是要保护弱者,医改也需要照顾我们这个社会群体中更多的弱者,要有底层情感,更多考虑底

公立医院薪酬制度开始试点

人社部、财政部、国家卫生计生委、国家中医药管理局联合发布《关于开展公立医院薪酬制度改革试点工作的指导意见》,提出在上海、江苏、福建等11个综合医改试点省份各选择3个市(州、区),除西藏外的其他省份各选择1个公立医院综合改革试点城市,开展为期1年的试点。

从2017到2030 医改“健康红利”值得期待

公立医院改革持续拓展深化、增加100个分级诊疗试点城市、医保覆盖率达95%……新一轮医药卫生体制改革进入第八个年头,医改已从打好基础转向提升质量、由单项突破转向综合推进,直面体制机制的深层顽疾,统筹推进重点领域和关键环节改革,为13亿人民带来了“健康红利”。 从2017年的序幕拉开,到2020年“十三五”收官之时,再到“健康中国”的2030年,医改这个民生热点有哪些改革让我们期盼?未来“

医改激励支持的地方名单出炉,快看看有没有你们那里!

根据国家卫生计生委办公厅和财政部办公厅《关于印发公立医院综合改革真抓实干成效明显地方激励措施实施办法(试行)的通知》(国卫办体改函〔2016〕1396号)的有关要求,现将公立医院综合改革真抓实干成效明显拟予激励支持的地方名单予以公示。公示截止日期为2017年1月22日。如有异议,请在公示期内以实名方式向国家卫生计生委体改司公立医院改革处反映。联系人:何俊联系电话:(010)62030835附件:公

三明市兑现2016年度院长、总会计师和全员目标年薪

22家公立医院院长最高年薪42.42万元、最低26.11万元,平均29.32万元,较2015年的26.19万元,增加3.13万元,增长11.95%,较改革前2012年的12.25万元,增加17.07万元,增幅达139.35%。总会计师的最高年薪为22.90万元、最低12.50万元,平均年薪14.13万元。22家公立医院工资总额总计9.83亿元,较2015年的8.95亿元,增长9.79%,较改革前2

特朗普破而不立 奥巴马医改咋办?

本周二, 由共和党全面控制的美国新一届国会参众二院议员宣誓就职。国会开张首日,共和党议员就提案废除奥巴马医改。 后任副总统彭斯也表示,特朗普在1月20日就任总统后,首要事务之一就是要废除奥巴马医改。 奥氏医保未来凶多吉少, 共和党执意要废除奥巴马这个引以为豪的立法政绩,民主党当然不会轻易放弃,因为这个发案尽管还不完善,但毕竟已经让上千万弱势群体拥有医疗保险,如果轻易取消,势必让这些人失去

Baidu
map
Baidu
map
Baidu
map